Skip to content

Research on FIBROSCAN noninvasive evaluation of liver fibrosis and cirrhosis in chronic hepatitis B

Research on FIBROSCAN noninvasive evaluation of liver fibrosis and cirrhosis in chronic hepatitis B

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DCS-07000039
Enrollment
Unknown
Registered
2007-12-27
Start date
2007-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver fibrosis and cirrhosis in chronic hepatitis B

Interventions

Gold Standard:
Index test:

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18-65 years, non-limited gender; 2. History of HBV or HBsAg positive >6 months up to now; 3. One month around FibroScan, with qualified biopsy specimen or liver biopsy for pathological diagnosis is accepted; 4. without chemical therapy history of powerful medicine to lower enzyme.(dimethyl diphenyl bicarboxylate and bicyclol); 5. Participant agreed and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Without signing the informed consent form; 2. Malignant tumor history or other end stage disease; 3. complied with HCV; 4. WBC <3.5*10^9/L, PLT <80*10^9/L, PTA <60%; 5. alcoholic or nonalcoholic fatty liver diseases, autoimmune liver diseases, inherited metabolic liver diseases, biliary tract diseases, parasitic diseases of hepatobiliary system; 6. Discompensatory cirrhosis (especially with ascites) etc; 7. pregnant or breast-feeding women.

Design outcomes

Primary

MeasureTime frame
Rigidity of liver;

Countries

China

Contacts

Public ContactJidong Jia
jiamd@263.com+86 010 63139816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 3, 2026